Repligen Q4 2024 Earnings Report
Key Takeaways
Repligen posted Q4 2024 revenue of $168 million, up 1% year-over-year. Adjusted EPS was $0.44, down from $0.48 in Q4 2023. The company reported a GAAP net loss of $34 million due to restructuring costs, but adjusted net income reached $25 million. Order growth in CDMO and capital equipment segments drove optimism for 2025.
Q4 revenue increased 1% year-over-year to $168 million.
GAAP net loss of $34 million, impacted by restructuring charges.
Adjusted EPS came in at $0.44, down from $0.48 in Q4 2023.
Strong order momentum in CDMO and capital equipment segments.
Repligen Revenue
Repligen EPS
Repligen Revenue by Segment
Forward Guidance
Repligen expects 8-12% reported revenue growth for FY 2025, driven by strong order momentum and CDMO expansion, while facing challenges from restructuring costs and currency headwinds.
Positive Outlook
- Forecasted revenue growth of 8-12% for FY 2025.
- Expected non-COVID revenue growth of 10-14%.
- Continued strong demand from CDMO and capital equipment markets.
- Launch of innovative AVIPure dsRNA resin for mRNA-based therapies.
- Recent Tantti Laboratory acquisition strengthens chromatography offerings.
Challenges Ahead
- Continued macroeconomic uncertainty in biotech investments.
- Restructuring costs impacting short-term profitability.
- Currency headwinds affecting international revenue.
- Competitive pressure in the bioprocessing sector.
- Ongoing monitoring of China market conditions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income